Pharma
Our Partners Print PDF
Hybrigenics has developed an extended network of partnerships with pharmaceutical and biotechnology companies as well as prestigious academic institutes:

Servier, France.
Drug target discovery alliance in cancer.

National Cancer Institute, USA.
Collaboration in small molecule drug screening (in vitro and in vivo).

Boston Biochem, USA.
Collaboration in developing advanced ubiquitin-specific proteases biochemical assays.

Nikem Research, Italy.
Collaboration in medicinal chemistry and protease-directed drug discovery.

Halle University, Germany.
Collaboration in molecular modelling and virtual screening.

Structural Genomic Consortium, Canada.
Collaboration in 3D structural studies.

Columbia University, USA.
Investigation of the ubiquitin/proteasome pathway.

University of Manchester, UK.
Investigation of ubiquitin-specific proteases functions.

Institut Pasteur, Paris - France.
R&D agreements with leading scientific teams working at the prestigious Institut Pasteur.

Institut Curie, Paris - France.
Collaboration with the Institut Curie to study the functional proteomics of cellular development, signalling and carcinogenesis.

Institut Cochin, Paris - France.
Collaboration with leading scientific teams on the ubiquitin/proteasome pathway and cell signaling.

Assistance Publique Hôpitaux de Paris, France.
Collaboration with clinicians on ubiquitin-specific proteases in cancer.
 
Meet us  at the International Conference 'Drug targets in the Ubiquitin Proteasome System; Targeting the ubiquitin system for drug discovery and development' (March 10-12, 2008; Berlin, Germany). An oral presentation will be given during the session 'E3 Ligase and DUB inhibitors' scheduled for 2:00 p.m. - 5:00 p.m. on Wednesday12th March.
© 2008 hybrigenics